The field of Hepatology has witnessed several significant advancements over the past few years. These advancements have revolutionized the approach towards diagnosis, management, and treatment of Hepatitis.
Novel diagnostic techniques such as Hepatitis B core-related antigen (HBcrAg) and Hepatitis B surface antigen quantification (HBsAg) have shown promising results in identifying the stages of chronic Hepatitis B infection. These techniques are also beneficial in monitoring the response to antiviral therapy. In Hepatitis C, the introduction of HCV RNA PCR tests has improved the detection of active infections.
Antiviral therapy has undergone a significant transformation with the introduction of Direct-acting antivirals (DAAs) for Hepatitis C. DAAs have shown to achieve sustained virological response rates of more than 90%. For Hepatitis B, tenofovir alafenamide fumarate (TAF) has emerged as a safer alternative to tenofovir disoproxil fumarate (TDF) with lower risks of renal and bone adverse events.
Vaccination remains a cornerstone in Hepatitis prevention. The Hepatitis B vaccine has been successful in significantly reducing the incidence of new infections. For Hepatitis C, although a vaccine is still under development, harm reduction strategies such as needle and syringe programs and opioid substitution therapy have shown to be effective in reducing transmission rates.
Research is currently underway to develop a cure for Hepatitis B and a vaccine for Hepatitis C. Additionally, the role of precision medicine in Hepatitis management is being explored, which involves tailoring treatment based on individual patient characteristics.
In conclusion, the advancements in Hepatitis management have improved patient outcomes significantly. However, the battle against Hepatitis is far from over. Continued research and innovation are imperative to further improve diagnosis, treatment, and prevention strategies.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation